See all treatments in the PatientsLikeMe system shared by patients just like you.
See also: Stalevo 150, Stalevo 200, Stalevo 50
What is Stalevo?
Stalevo is a brand name for a combination of the drugs l-dopa, carbidopa, and entacapone. L-dopa is the precursor to dopamine, carbidopa slows the breakdown of l-dopa, whilst entacapone improves the efficacy of l-dopa.
Read more...
199 patients in the community are taking or have taken Stalevo.
| Reason | # Patients | Percentage of patients |
|---|---|---|
| Treat Parkinson's | 158 | 79% |
| Stiffness/spasticity | 11 | 5% |
| Other | 8 | 4% |
| Mobility | 2 | 1% |
| General health | 2 | 1% |
| Slowness | 2 | 1% |
| Brain fog | 1 | <1% |
| Memory problems | 1 | <1% |
| disease-related symptoms | 1 | <1% |
| Slurred speech | 1 | <1% |
| Don't know | 1 | <1% |
| Support another treatment | 1 | <1% |
| 0 mg day | 0 mg none | 0.05 mg day | 3 mg day | 4 mg day | 4 other day | 4 day | 6 mg day | 25 mg day | 37.5 mg day | 50 mg day | 80 mg day | 100 mg day | 125 mg day | 150 mg day | 200 mg day | 200 other day | 250 mg day | 300 mg day | 350 mg day | 400 mg day | 450 mg day | 500 mg day | 600 mg day | 700 mg day | 750 mg day | 800 mg day | 850 mg day | 900 mg day | 1000 mg day | 1200 mg day | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
17
|
1
|
1
|
1
|
2
|
1
|
1
|
2
|
1
|
1
|
6
|
1
|
13
|
1
|
8
|
12
|
1
|
2
|
24
|
1
|
16
|
8
|
5
|
20
|
2
|
4
|
8
|
1
|
3
|
4
|
2
|
||
How long current patients have been taking Stalevo or how long patients were taking Stalevo before stopping.
Results from 13 patient evaluations. See the overall results and all individual evaluations.
| Major | 92% | 11 |
|---|---|---|
| Can't tell | 8% | 1 |
Treat Parkinson's
| Severe | 0% | 0 |
|---|---|---|
| Moderate | 15% | 2 |
| Mild | 38% | 5 |
| None | 46% | 6 |
Top reported side-effects include: legs cramping when wearing off, tremors increase when wearing off, Slight nausea
Summary results are based on 13 individual responses. For more information, see overall results for Adherence, Burden and Cost.